156 related articles for article (PubMed ID: 23669150)
1. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation.
Le Fur E; Malhaire JP; Nowak E; Rousseau B; Erauso A; Pene-Baverez D; Papin G; Delage F; Perrouin-Verbe MA; Fournier G; Pradier O; Valeri A
Brachytherapy; 2013; 12(6):589-95. PubMed ID: 23669150
[TBL] [Abstract][Full Text] [Related]
2. Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.
Le Fur E; Malhaire JP; Baverez D; Delage F; Perrouin-Verbe MA; Schlurmann F; Guerif S; Fournier G; Pradier O; Valeri A
Strahlenther Onkol; 2012 Dec; 188(12):1091-5. PubMed ID: 23142920
[TBL] [Abstract][Full Text] [Related]
3. Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution.
Ong WL; Matheson B; Millar J
Brachytherapy; 2017; 16(2):313-322. PubMed ID: 28017293
[TBL] [Abstract][Full Text] [Related]
4. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up.
Keyes M; Miller S; Moravan V; Pickles T; Liu M; Spadinger I; Lapointe V; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):649-55. PubMed ID: 19211199
[TBL] [Abstract][Full Text] [Related]
5. The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy.
Crook J; Toi A; McLean M; Pond G
Brachytherapy; 2002; 1(3):131-7. PubMed ID: 15090275
[TBL] [Abstract][Full Text] [Related]
6. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?
Keyes M; Schellenberg D; Moravan V; McKenzie M; Agranovich A; Pickles T; Wu J; Liu M; Bucci J; Morris WJ
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):825-34. PubMed ID: 16458775
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
8. Is there a relation between the radiation dose to the different sub-segments of the lower urinary tract and urinary morbidity after brachytherapy of the prostate with I-125 seeds?
Steggerda MJ; Witteveen T; van den Boom F; Moonen LM
Radiother Oncol; 2013 Nov; 109(2):251-5. PubMed ID: 24060176
[TBL] [Abstract][Full Text] [Related]
9. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
[TBL] [Abstract][Full Text] [Related]
10. Urinary symptom flare following I-125 prostate brachytherapy.
Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
[TBL] [Abstract][Full Text] [Related]
11. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
[TBL] [Abstract][Full Text] [Related]
13. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years.
Stone NN; Stock RG
Urology; 2007 Feb; 69(2):338-42. PubMed ID: 17320674
[TBL] [Abstract][Full Text] [Related]
14. Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study.
Ohashi T; Yorozu A; Saito S; Tanaka N; Katayama N; Kojima S; Maruo S; Kikuchi T; Dokiya T; Fukushima M; Yamanaka H
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):141-9. PubMed ID: 26279031
[TBL] [Abstract][Full Text] [Related]
15. Decline in acute urinary toxicity: a long-term study in 2011 patients with prostate brachytherapy within a provincial institution.
Chan EK; Keyes M; Pickles T; Lapointe V; Spadinger I; McKenzie M; Morris WJ
Brachytherapy; 2014; 13(1):46-52. PubMed ID: 24210697
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
Roeloffzen EM; van Vulpen M; Battermann JJ; van Roermund JG; Saibishkumar EP; Monninkhof EM
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):737-44. PubMed ID: 20888131
[TBL] [Abstract][Full Text] [Related]
17. Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy.
Roeloffzen EM; Battermann JJ; van Deursen MJ; Monninkhof EM; Visscher MI; Moerland MA; van Vulpen M
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1072-9. PubMed ID: 20615621
[TBL] [Abstract][Full Text] [Related]
18. Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS).
Tanaka N; Yorozu A; Kikuchi T; Higashide S; Kojima S; Ohashi T; Katayama N; Nakamura K; Saito S; Dokiya T; Fukushima M;
Brachytherapy; 2019; 18(4):484-492. PubMed ID: 31072729
[TBL] [Abstract][Full Text] [Related]
19. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
20. Probability of late rectal morbidity in 125I prostate brachytherapy.
Waterman FM; Dicker AP
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):342-53. PubMed ID: 12527047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
